Role of surgery combined with kinase inhibition in the management of gastrointestinal Stromal Tumor (GIST)

Annals of Surgical Oncology

Volumn 17, Issue 10, 2010, Pages 2585-2600

  Hohenberger, Peter ^a   Eisenberg, Burton ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PHOSPHOTRANSFERASE; PLACEBO; SUNITINIB;

ADJUVANT THERAPY; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURGERY; CLINICAL TRIAL; DRUG EFFICACY; ENZYME INHIBITION; GASTRECTOMY; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; INOPERABLE CANCER; LAPAROSCOPIC SURGERY; LYMPHADENECTOMY; METASTASIS; PEROPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; PRIMARY TUMOR; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; GASTROINTESTINAL STROMAL TUMORS; HUMANS; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 78049463609     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-1053-9     Document Type: Review

References (118)

1. PG Casali L Jost P Reichardt M Schlemmer JY Blay 2009 Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 20 Suppl 4 64 67 19454466
2. NCCN. The NCCN soft tissue sarcoma clinical practice guidelines in oncology (version 1, 2009). (C) 2009 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed 1 Jul 2009. To view the most recent and complete version of the guideline, go online to www.nccn.org. 2009.
3. S Singer BP Rubin ML Lux CJ Chen GD Demetri CD Fletcher, et al. 2002 Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors J Clin Oncol 20 3898 3905 1:CAS:528:DC%2BD38XntVynsLo%3D 12228211
4. I Hassan YN You R Shyyan EJ Dozois TC Smyrk SH Okuno, et al. 2008 Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis Ann Surg Oncol 15 52 59 18000711
5. C Langer B Gunawan P Schuler W Huber L Fuzesi H Becker 2003 Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours Br J Surg 90 332 339 1:STN:280:DC%2BD3s%2Fot1Oitg%3D%3D 12594669
6. EH Ng RE Pollock MF Munsell EN Atkinson MM Romsdahl 1992 Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging Ann Surg 215 68 77 1:STN:280: DyaK387hslOntw%3D%3D 1731651
7. KC Conlon ES Casper MF Brennan 1995 Primary gastrointestinal sarcomas: analysis of prognostic variables Ann Surg Oncol 2 26 31 1:STN:280: DyaK2M7js1SntQ%3D%3D 7834450
8. RP DeMatteo JJ Lewis D Leung SS Mudan JM Woodruff MF Brennan 2000 Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival Ann Surg 231 51 58 1:STN:280:DC%2BD3c7gtVSmtQ%3D%3D 10636102
9. PJ Roberts B Eisenberg 2002 Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease Eur J Cancer 38 Suppl 5 S37 S38 12528771
10. R Dagher M Cohen G Williams M Rothmann J Gobburu G Robbie, et al. 2002 Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors Clin Cancer Res 8 3034 3038 1:CAS:528:DC%2BD38XosFKiu7k%3D 12374669
11. CD Blanke C Rankin GD Demetri CW Ryan M von Mehren RS Benjamin, et al. 2008 Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 J Clin Oncol 26 626 632 1:CAS:528:DC%2BD1cXis1alsLs%3D 18235122
12. GD Demetri M von Mehren CD Blanke AD Van den Abbeele B Eisenberg PJ Roberts, et al. 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 472 480 1:CAS:528: DC%2BD38XmtV2nt7s%3D 12181401
13. US Food and Drug Administration. FDA approves Gleevec to prevent recurrence of rare gastrointestinal cancer. http://www.fda.gov/bbs/topics/NEWS/ 2008/NEW01931.html. In Edition 2008.
14. DeMatteo R, Owzar K, Maki R, Pisters P, Blackstein M, Antonescu C, et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American intergroup phase III trial ACOSOG Z9001. [Abstract No.10079]. In 2007 ASCO annual meeting. Edition Chicago, Illinois: 2007.
15. RP DeMatteo KV Ballman CR Antonescu RG Maki PW Pisters GD Demetri, et al. 2009 Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial Lancet 373 1097 1104 1:CAS:528:DC%2BD1MXjslOltro%3D 19303137
16. RP DeMatteo RG Maki S Singer M Gonen MFCR Brennan 2007 A. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor Ann Surg 245 347 352 17435539
17. A Gronchi M Fiore F Miselli MS Lagonigro P Coco A Messina, et al. 2007 Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST Ann Surg 245 341 346 17435538
18. CP Raut M Posner J Desai JA Morgan S George D Zahrieh, et al. 2006 Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors J Clin Oncol 24 2325 2331 1:CAS:528:DC%2BD28XlvV2ksbw%3D 16710031
19. P Rutkowski Z Nowecki P Nyckowski W Dziewirski U Grzesiakowska A Nasierowska-Guttmejer, et al. 2006 Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate J Surg Oncol 93 304 311 16496358
20. SJ Sym MH Ryu JL Lee HM Chang TW Kim HC Kim, et al. 2008 Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs) J Surg Oncol 98 27 33 18452195
21. SJ Neuhaus MA Clark AJ Hayes JM Thomas I Judson 2005 Surgery for gastrointestinal stromal tumour in the post-imatinib era ANZ J Surg 75 165 172 15777399
22. CD Blanke GD Demetri M von Mehren MC Heinrich B Eisenberg JA Fletcher, et al. 2008 Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT J Clin Oncol 26 620 625 1:CAS:528:DC%2BD1cXis1alsL0%3D 18235121
23. BL Eisenberg J Harris CD Blanke GD Demetri MC Heinrich JC Watson, et al. 2009 Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665 J Surg Oncol 99 42 47 1:CAS:528:DC%2BD1MXhvFCjur0%3D 18942073
24. U Ronellenfitsch W Staiger G Kahler P Strobel M Schwarzbach P Hohenberger 2009 Perioperative and oncological outcome of laparoscopic resection of gastrointestinal stromal tumour (GIST) of the stomach Diagn Ther Endosc 2009 286138 19343179
25. M Hellan VK Maker 2006 Transvaginal excision of a large rectal stromal tumor: an alternative Am J Surg 191 121 123 16399120
26. C Dong C Jun-Hui Y Xiao-Jun K Mei W Bo J Chen-Fe, et al. 2007 Gastrointestinal stromal tumors of the rectum: Clinical, pathologic, immunohistochemical characteristics and prognostic analysis Scand J Gastroenterol. 42 1221 1229 17852882
27. CR Changchien MC Wu WS Tasi R Tang JM Chiang JS Chen, et al. 2004 Evaluation of prognosis for malignant rectal gastrointestinal stromal tumor by clinical parameters and immunohistochemical staining Dis Colon Rectum. 47 1922 1929 15622586
28. CD Fletcher JJ Berman C Corless F Gorstein J Lasota BJ Longley, et al. 2002 Diagnosis of gastrointestinal stromal tumors: A consensus approach Hum Pathol. 33 459 465 12094370
29. M Miettinen J Lasota 2006 Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis Arch Pathol Lab Med. 130 1466 1478 1:CAS:528:DC%2BD28XhtFyhs7%2FN 17090188
30. RP DeMatteo JS Gold L Saran M Gonen KH Liau RG Maki, et al. 2008 Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST) Cancer. 112 608 615 18076015
31. JA Crosby CN Catton A Davis J Couture B O'Sullivan R Kandel, et al. 2001 Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database Ann Surg Oncol. 8 50 59 1:STN:280: DC%2BD3M7lsFeksg%3D%3D 11206225
32. TS Emory LH Sobin L Lukes DH Lee TJ O'Leary 1999 Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site Am J Surg Pathol. 23 82 87 1:STN:280:DyaK1M7gtlOrsA%3D%3D 9888707
33. TW Kim H Lee YK Kang MS Choe MH Ryu HM Chang, et al. 2004 Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors Clin Cancer Res. 10 3076 3081 1:CAS:528:DC%2BD2cXjs12ltr8%3D 15131046
34. J Martin A Poveda A Llombart-Bosch R Ramos JA López-Guerrero J García del Muro, et al. 2005 Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS) J Clin Oncol. 23 6190 6198 1:CAS:528:DC%2BD2MXhtVKgtbrO 16135486
35. P Bucher JF Egger P Gervaz F Ris D Weintraub P Villiger, et al. 2006 An audit of surgical management of gastrointestinal stromal tumours (GIST) Eur J Surg Oncol. 32 310 314 1:STN:280:DC%2BD287lvF2lsA%3D%3D 16414236
36. P Bumming H Ahlman J Andersson JM Meis-Kindblom LG Kindblom B Nilsson 2006 Population-based study of the diagnosis and treatment of gastrointestinal stromal tumours Br J Surg. 93 836 843 1:STN:280:DC%2BD28znsVKjtg%3D%3D 16705644
37. JP Pierie U Choudry A Muzikansky BY Yeap WW Souba MJ Ott 2001 The effect of surgery and grade on outcome of gastrointestinal stromal tumors Arch Surg. 136 383 389 1:STN:280:DC%2BD3M3kvVemsA%3D%3D 11296107
38. YY Hou F Grabellus F Weber Y Zhou YS Tan J Li, et al. 2009 Impact of KIT and PDGFRA gene mutations on prognosis of patients with gastrointestinal stromal tumors after complete primary tumor resection J Gastrointest Surg. 13 1583 1592 19291337
39. JN Shah W Sun RR Seethala VA Livolsi RD Fry GG Ginsberg 2005 Neoadjuvant therapy with imatinib mesylate for locally advanced GI stromal tumor Gastrointest Endosc 61 625 627 15812427
40. BK Goh PK Chow KL Chuah WM Yap WK Wong 2006 Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate Eur J Surg Oncol. 32 961 963 1:STN:280: DC%2BD28njvVGmtA%3D%3D 16842963
41. P Bumming J Andersson JM Meis-Kindblom H Klingenstierna K Engström U Stierner, et al. 2003 Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients Br J Cancer. 89 460 464 1:STN:280:DC%2BD3szlsFansA%3D%3D 12888812
42. P Hohenberger C Langer S Pistorius I Iesalnieks E Wardelmann P Reichardt, et al. 2006 Indication and results of surgery following imatinib treatment of locally advanced or metastatic GI stromal tumors (GIST) J Clin Oncol 24 9500 Meeting Abstracts
43. T Heinicke E Wardelmann T Sauerbruch HJ Tschampa A Glasmacher H Palmedo 2005 Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography Anticancer Res. 25 4591 4594 1:CAS:528:DC%2BD2MXhtlWgtL%2FI 16334147
44. D Goldstein BS Tan M Rossleigh W Haindl B Walker J Dixon 2005 Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response-an AGITG study Oncology. 69 326 332 16293972
45. DW Townsend JPJ Carney JT Yap NC Hall 2004 PET/CT today and tomorrow J Nucl Med. 45 4S 14 14736831
46. GD Demetri AT van Oosterom CR Garrett ME Blackstein MH Shah J Verweij, et al. 2006 Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet. 368 1329 1338 1:CAS:528:DC%2BD28XhtVOrtL%2FL 17046465
47. EP Rock V Goodman JX Jiang K Mahjoob SL Verbois D Morse, et al. 2007 Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma Oncologist. 12 107 113 1:CAS:528:DC%2BD2sXhvVaksro%3D 17227905
48. A Le Cesne M Van Glabbeke J Verweij PG Casali M Findlay P Reichardt, et al. 2009 Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: The Intergroup EORTC-ISG-AGITG Phase III Trial J Clin Oncol. 27 3969 3974 1:CAS:528:DC%2BD1MXhtFCgsbrO 19620483
49. J-Y Blay A Le Cesne I Ray-Coquard B Bui F Duffaud C Delbaldo, et al. 2007 Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group J Clin Oncol. 25 1107 1113 1:CAS:528:DC%2BD2sXksVyrs7s%3D 17369574
50. Adenis A, Cassier PA, Bui BN, Rios, F. Duffaud, F. Bertucci, et al. Does interruption of imatinib (IM) in responding patients after three years of treatment influence outcome of patients with advanced GIST included in the BFR14 trial? [abstract No.10522]. J Clin Oncol. 2008;26 (May 20 Supplement).
51. M Rios A Lecesne B Bui A Adenis F Bertucci F Duffaud, et al. 2007 Interruption of imatinib (IM) in GIST patients with advanced disease after one year of treatment: Updated results of the prospective French Sarcoma Group randomized phase III trial on long term survival ASCO Meeting Abstracts 25 10016
52. G Demetri Y Wang E Wehrle A Racine Z Nikolova CD Blanke, et al. 2009 Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors J Clin Oncol. 27 3141 3147 1:CAS:528:DC%2BD1MXhtFWitb3K 19451435
53. GD Demetri PG Casali J-Y Blay M von Mehren JA Morgan R Bertulli, et al. 2009 A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors Clin Cancer Res. 15 5910 5916 1:CAS:528:DC%2BD1MXhtFars7rK 19723647
54. CAMN107A2201. A randomized, open-label, study of nilotinib versus best supportive care with or without a tyrosine kinase inhibitor (investigator's choice) in GIST patients resistant to both imatinib and sunitinib (ENEST). www.ClinicalTrials.gov. Identifier: NCT00471328. Accessed 19 Aug 2009.
55. CAMN107G2301. A randomized, open label, multi-center phase iii study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST). www.ClinicalTrials.gov. Identifier: NCT00785785. Accessed 19 Aug 2009.
56. CAMN107DDE06. An open-label, multi-center, single-arm study to evaluate the efficacy of nilotinib in adult patients with metastatic or unresectable gastrointestinal stromal tumors in first line treatment. (OPEN); EUDRACT- Nr. 2008-000358-11. www.ClinicalTrials.gov. Identifier: NCT00756509; Accessed 13 Oct 2009.
57. ME Blackstein J-Y Blay C Corless DK Driman R Riddell D Soulieres, et al. 2006 Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment Can J Gastroenterol. 20 157 163 16550259
58. M Montemurro S Dirnhofer M Bornerc R Burkhard N Demartines M Furrer, et al. 2008 Diagnosis and treatment of GIST in Switzerland Schweiz Med Forum. 8 544 549
59. T Nishida S Hirota A Yanagisawa Y Sugino M Minami Y Yamamura, et al. 2008 Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version Int J Clin Oncol. 13 416 430 18946752
60. T de Pas PG Casali S Toma A Romanini B Massidda A Comandone, et al. 2003 Gastrointestinal stromal tumors: should they be treated with the same systemic chemotherapy as other soft tissue sarcomas? Oncology. 64 186 188 12566918
61. JH Edmonson RS Marks JC Buckner MR Mahoney 2002 Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas Cancer Invest. 20 605 612 1:CAS:528:DC%2BD38XntFyrtr0%3D 12197215
62. RP DeMatteo 2002 The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571) Ann Surg Oncol. 9 831 839 12417503
63. H Joensuu C Fletcher S Dimitrijevic S Silberman P Roberts G Demetri 2002 Management of malignant gastrointestinal stromal tumours Lancet Oncol. 3 655 664 1:CAS:528:DC%2BD38Xotlygs7Y%3D 12424067
64. DM Byrd GD Demetri H Joensuu M von Mehren B Heinrich, et al. 2007 Evaluation of imatinib mesylate (IM) in patients with large volume gastrointestinal stromal tumors (GISTs) J Clin Oncol 25 10054 Meeting Abstracts
65. RS Benjamin CD Blanke JY Blay S Bonvalot B Eisenberg 2006 Management of gastrointestinal stromal tumors in the imatinib era: selected case studies Oncologist. 11 9 20 16401709
66. K Jacobs C de Gheldere P Vanclooster 2006 A ruptured gastrointestinal stromal tumour of the transverse mesocolon: a case report Acta Chir Belg. 106 218 221 1:STN:280:DC%2BD28zkvVWitw%3D%3D 16761482
67. IR Lai RH Hu KJ Chang 2005 Is imatinib justified as an adjuvant chemotherapy for patients with recurrent gastrointestinal stromal tumors Hepatogastroenterology. 52 826 828 15966213
68. B Nilsson K Sjolund LG Kindblom JM Meis-Kindblom P Bümming O Nilsson, et al. 2007 Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST) Br J Cancer. 96 1656 1658 1:CAS:528:DC%2BD2sXlvVShtrg%3D 17533389
69. Zhan WH, China Gastrointestinal Cooperative G. Efficacy and safety of adjuvant post-surgical therapy with imatinib in GIST patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial. J Clin Oncol. 2007; 25:10045; full paper in: Zhonghua Wei Chang Wai Ke Za Zhi. 2006;9:383-7. [meeting abstracts].
70. DeMatteo RP, Owzar K, Antonescu CR, Maki R, Demetri GD, McCarter M, et al. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000. [Abstract No. 8]. In 2008 ASCO gastrointestinal cancers symposium. Edition Orlando, Florida: 2008.
71. RP DeMatteo CR Antonescu V Chadaram, et al. 2005 Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: Safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000 J Clin Oncol 23 9009 (Meeting Abstracts)
72. Scandinavian Sarcoma Group. SSGXVIII/AIO. short (12 months) versus long (36 months) duration of adjuvant treatment with the tyrosine kinase inhibitor imatinib mesylate of operable GIST with a high risk of recurrence. (NCT identifier: NCT00116935.). In Edition ClinicalTrials.gov, United States National Institutes of Health. Accessed 27 Feb 2009.
73. European Organization for Research and Treatment of Cancer, Italian Sarcoma Group, Federation Nationale des Centres de Lutte Contre le Cancer, Sarcomas GEdIe. EORTC 62024. Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant imatinib mesylate (Glivec) versus no further therapy after complete surgery. (NCT identifier: NCT00103168.) In Edition ClinicalTrials.gov, United States National Institutes of Health. Accessed 27 Feb 2009.
74. M Miettinen J Lasota 2006 Gastrointestinal stromal tumors: pathology and prognosis at different sites Semin Diagn Pathol. 23 70 83 17193820
75. BL Eisenberg I Judson 2004 Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy Ann Surg Oncol. 11 465 475 15123459
76. D Katz A Segal Y Alberton O Jurim P Reissman R Catane, et al. 2004 Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor Anticancer Drugs. 15 599 602 1:CAS:528:DC%2BD2cXkvV2ntb4%3D 15205603
77. CL Liu MJ Huang SC Lin KM Chang CY Tzen 2004 Neo-adjuvant STI571 therapy for high-risk gastrointestinal stromal tumour ANZ J Surg. 74 289 290 15043750
78. SS Lo GI Papachristou SD Finkelstein WP Conroy WH Schraut RK Ramanathan 2005 Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: report of a case Dis Colon Rectum. 48 1316 1319 15793646
79. MB Loughrey C Mitchell GB Mann M Michael PM Waring 2005 Gastrointestinal stromal tumour treated with neoadjuvant imatinib J Clin Pathol. 58 779 781 1:STN:280:DC%2BD2Mzis1aisQ%3D%3D 15976351
80. F Haller S Detken HJ Schulten N Happel B Gunawan J Kuhlgatz, et al. 2007 Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations Ann Surg Oncol. 14 526 532 17139461
81. M Salazar A Barata S Andre J Venancio I Francisco M Cravo, et al. 2006 First report of a complete pathological response of a pelvic GIST treated with imatinib as neoadjuvant therapy Gut. 55 585 586 1:STN:280:DC%2BD287kt1Ghsw%3D%3D 16531543
82. Radiation Therapy Oncology Group National Cancer Institute (NCI), American College of Radiology Imaging Network, Eastern Cooperative Oncology Group. RTOG S-0132. A phase II trial of neoadjuvant/adjuvant STI-571 (Gleevec NSC No.716051) for primary and recurrent operable malignant GIST expressing the KIT receptor tyrosine kinase (CD117). (NCT identifier: NCT00028002.). In Edition ClinicalTrials.gov, United States National Institutes of Health. Accessed 27 Feb 2009.
83. JC McAuliffe KK Hunt AJ Lazar H Choi W Qiao P Thall, et al. 2009 A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis Ann Surg Oncol. 16 910 919 18953611
84. Technische Universität München. CSTI571-BDE43. Open-label trial of neoadjuvant imatinib mesylate (Glivec) in patients with locally advanced malignant gastrointestinal stromal tumors (GIST) expressing c-Kit or platelet-derived growth factor receptor-alpha. (NCT Identifier: NCT00112632.). In Edition ClinicalTrials.gov, United States National Institutes of Health. Accessed 27 Feb 2009.
85. JS Gold RP DeMatteo 2006 Combined surgical and molecular therapy: the gastrointestinal stromal tumor model Ann Surg. 244 176 184 16858179
86. JS Gold RP DeMatteo 2007 Neoadjuvant therapy for gastrointestinal stromal tumor (GIST): racing against resistance Ann Surg Oncol. 14 1247 1248 17265116
87. S Stroobants J Goeminne M Seegers S Dimitrijevic P Dupont J Nuyts, et al. 2003 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec) Eur J Cancer. 39 2012 2020 1:CAS:528:DC%2BD3sXmvVKgt74%3D 12957455
88. SS Yoon KK Tanabe 2007 Should surgical resection be combined with imatinib therapy for locally advanced or metastatic gastrointestinal stromal tumors? Ann Surg Oncol. 14 1784 1786 17356951
89. RH Andtbacka CS Ng CL Scaife JN Cormier KK Hunt PW Pisters, et al. 2007 Surgical resection of gastrointestinal stromal tumors after treatment with imatinib Ann Surg Oncol 14 14 24 17072676
90. S Bonvalot H Eldweny CL Pechoux D Vanel P Terrier A Cavalcanti, et al. 2006 Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era Ann Surg Oncol. 13 1596 1603 1:STN:280:DC%2BD28jhvVahtQ%3D%3D 16957966
91. GF Samelis KA Ekmektzoglou GC Zografos 2007 Gastrointestinal stromal tumours: clinical overview, surgery and recent advances in imatinib mesylate therapy Eur J Surg Oncol. 33 942 950 1:STN:280:DC%2BD2srmtlWgsg%3D%3D 17196360
92. RP DeMatteo 2007 Treatment of advanced gastrointestinal stromal tumor: a marriage of targeted therapy and surgery? Ann Surg Oncol. 14 1 2 16957967
93. J Hasegawa T Kanda S Hirota M Fukuda A Nishitani T Takahashi, et al. 2007 Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy Int J Clin Oncol. 12 212 217 17566845
94. EORTC-STBSG 62063. A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to imatinib mesylate. www.ClinicalTrials.gov. identifier: NCT00956072. Accessed 19 Aug 2009.
95. Y Otani M Ohgami N Igarashi M Kimata T Kubota 2000 Kumai Koichiro, et al Laparoscopic wedge resection of gastric submucosal tumors. Surg Laparosc Endosc Percutan Tech 10 19 23 1:STN:280:DC%2BD3cvpsVCktw%3D%3D
96. K Ludwig R Weiner J Bernhardt 2003 Minimally invasive resections of gastric tumors Chirurg. 74 632 637 1:STN:280:DC%2BD3szltVGmuw%3D%3D 12883790
97. Y Mochizuki Y Kodera M Fujiwara S Ito Y Yamamura A Sawaki, et al. 2006 Laparoscopic wedge resection for gastrointestinal stromal tumors of the stomach: initial experience Surg Today. 36 341 347 16554991
98. A Hindmarsh B Koo MP Lewis M Rhodes 2005 Laparoscopic resection of gastric gastrointestinal stromal tumors Surg Endosc. 19 1109 1112 1:STN:280:DC%2BD2MrlvVOhsw%3D%3D 16021371
99. BD Matthews RM Walsh KW Kercher RF Sing BL Pratt GA Answini, et al. 2002 Laparoscopic vs open resection of gastric stromal tumors Surg Endosc. 16 803 807 1:STN:280:DC%2BD383lvVahsw%3D%3D 11997826
100. SM Choi MC Kim GJ Jung HH Kim HC Kwon SR Choi, et al. 2007 Laparoscopic wedge resection for gastric GIST: long-term follow-up results Eur J Surg Oncol. 33 444 447 17174060
101. SQ Nguyen CM Divino JL Wang SH Dikman 2006 Laparoscopic management of gastrointestinal stromal tumors Surg Endosc. 20 713 716 1:STN:280: DC%2BD283lsFCktw%3D%3D 16502196
102. IR Lai WJ Lee SC Yu 2006 Minimally invasive surgery for gastric stromal cell tumors: intermediate follow-up results J Gastrointest Surg. 10 563 566 16627222
103. R Berindoague EM Targarona X Feliu V Artigas C Balagué A Aldeano, et al. 2006 Laparoscopic resection of clinically suspected gastric stromal tumors Surg Innov. 13 231 237 17227921
104. A Privette L McCahill E Borrazzo RM Single R Zubarik 2008 Laparoscopic approaches to resection of suspected gastric gastrointestinal stromal tumors based on tumor location Surg Endosc. 22 487 494 1:STN:280: DC%2BD1c%2FpvFWntg%3D%3D 17712592
105. S Basu S Balaji DH Bennett N Davies 2007 Gastrointestinal stromal tumors (GIST) and laparoscopic resection Surg Endosc. 21 1685 1689 17661137
106. SR Granger MD Rollins SJ Mulvihill RE Glasgow 2006 Lessons learned from laparoscopic treatment of gastric and gastroesophageal junction stromal cell tumors Surg Endosc. 20 1299 1304 1:STN:280:DC%2BD28vptFalsQ%3D%3D 16865626
107. EL Bedard J Mamazza CM Schlachta EC Poulin 2006 Laparoscopic resection of gastrointestinal stromal tumors: not all tumors are created equal Surg Endosc. 20 500 503 1:STN:280:DC%2BD287gslerug%3D%3D 16437270
108. M Iwahashi K Takifuji T Ojima M Nakamura M Nakamori Y Nakatani, et al. 2006 Surgical management of small gastrointestinal stromal tumors of the stomach World J Surg. 30 28 35 16369707
109. F Catena M Di Battista P Fusaroli L Ansaloni V Di Scioscio D Santini, et al. 2008 Laparoscopic treatment of gastric GIST: report of 21 cases and literature's review J Gastrointest Surg. 12 561 568 18040747
110. M Nakamori M Iwahashi M Nakamura K Tabuse K Mori K Taniguchi, et al. 2008 Laparoscopic resection for gastrointestinal stromal tumors of the stomach Am J Surg. 196 425 429 18466871
111. JA Sexton RA Pierce VJ Halpin JC Eagon WG Hawkins DC Linehan, et al. 2008 Laparoscopic gastric resection for gastrointestinal stromal tumors Surg Endosc. 22 2583 2587 18322738
112. KL Huguet RM Rush Jr DJ Tessier RT Schlinkert RA Hinder GG Grinberg, et al. 2008 Laparoscopic gastric gastrointestinal stromal tumor resection: the mayo clinic experience Arch Surg. 143 587 590 18559753 discussion 591
113. CC Hepworth D Menzies RW Motson 2000 Minimally invasive surgery for posterior gastric stromal tumors Surg Endosc. 14 349 353 1:STN:280: DC%2BD3c3ltlynug%3D%3D 10790553
114. VK Li WK Hung CK Chung MW Ying BY Lam DM Kan, et al. 2008 Laparoscopic intragastric approach for stromal tumours located at the posterior gastric wall Asian J Surg. 31 6 10 18334462
115. J Nishimura K Nakajima T Omori T Takahashi A Nishitani T Ito, et al. 2007 Surgical strategy for gastric gastrointestinal stromal tumors: laparoscopic vs open resection. Surg Endosc. 21 875 878
116. N Hiki Y Yamamoto 2008 Fukunaga, Yamaguchi T, Nunobe S, Tokunaga M, T et al Laparoscopic and endoscopic cooperative surgery for gastrointestinal stromal tumor dissection. Surg Endosc. 22 1729 1735 1:STN:280:DC%2BD1czmvVSitw%3D%3D
117. D Wilhelm S von Delius M Burian A Schneider E Frimberger A Meining, et al. 2008 Simultaneous use of laparoscopy and endoscopy for minimally invasive resection of gastric subepithelial masses - analysis of 93 interventions World J Surg. 32 1021 1028 1:STN:280:DC%2BD1czitFOnsA%3D%3D 18338207
118. A Dimitrakopoulou-Strauss P Hohenberger U Haberkorn HR Macke M Eisenhut LG Strauss 2007 68 Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG J Nucl Med 48 1245 1250 1:CAS:528:DC%2BD2sXhtVSktb%2FO 17631559